Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus

NCT01408199 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT01408199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01408199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2010
Completion date
August 31, 2011
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus